San Francisco, CA, United States of America

Brian A Irving


Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 525(Granted Patents)


Company Filing History:


Years Active: 1994-2002

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Brian A Irving: Innovator in Chimeric Protein Technology

Introduction

Brian A Irving is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric proteins. With a total of 3 patents, his work has implications for various medical and therapeutic applications.

Latest Patents

One of his latest patents focuses on chimeric chains for receptor-associated signal transduction pathways. This patent describes chimeric proteins and the DNA encoding them, characterized by an extracellular domain that can bind to a ligand in a non-MHC restricted manner. The proteins also include a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The unique combination of these domains, which are not naturally found together, allows for the transduction of signals within the cell. This innovation can induce cells to perform various functions related to the signaling pathway. The chimeric DNA can be utilized to modify lymphocytes and hematopoietic stem cells, serving as precursors to several important cell types.

Career Highlights

Throughout his career, Brian has worked with prominent organizations such as Cell Genesys, Inc. and the University of California. His experience in these institutions has allowed him to advance his research and contribute to the field of biotechnology significantly.

Collaborations

Brian has collaborated with notable colleagues, including Daniel J Capon and Arthur Weiss. These partnerships have further enriched his research endeavors and innovations.

Conclusion

Brian A Irving stands out as an influential inventor in the realm of chimeric protein technology. His patents and collaborations reflect his commitment to advancing biotechnological applications for therapeutic purposes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…